Science and Research

A Phase 2b, Randomised, Double-Blind, Placebo Controlled Dose Range Finding Study to Assess Efficacy and Safety of Multiple Dose Levels of Inhaled AZD8630 Given Once Daily for 12 Weeks in Adults with Uncontrolled Asthma at Risk of Exacerbations (LEVANTE).

To evaluate the effect of AZD8630 as compared to placebo on time to first CompEx Asthma event in patients with uncontrolled asthma at risk of exacerbations.

Study details
Study-ID: 2024-514228-18-00
Study-ID: 2024-514228-18-00
DZL Disease Area: AA
DZL Disease Area: AA
Study Type: Interventional
Study Type: Interventional
DZL Role: DZL on steering board
DZL Role: DZL on steering board
Funding: Externally - industry
Funding: Externally - industry
DZL Participating Sites: ARCN
DZL Participating Sites: ARCN
Start Date: 16.01.2025
Completion Date: 05.02.2026
Status: Closed
Status: Closed
DZL on steering board
Link to Study


close
chevron-down

Unsere Seite verwendet Cookies und ähnliche Technologien. Mit der Nutzung der Webseite stimmen Sie der Verwendung von Cookies zu. Mehr Informationen dazu finden Sie in unserer Datenschutzerklärung.